Details for Patent: 10,532,993
✉ Email this page to a colleague
Which drugs does patent 10,532,993 protect, and when does it expire?
Patent 10,532,993 protects RHOPRESSA and ROCKLATAN and is included in two NDAs.
This patent has nine patent family members in six countries.
Summary for Patent: 10,532,993
| Title: | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| Abstract: | Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds. |
| Inventor(s): | deLong; Mitchell A. (Chapel Hill, NC), Sturdivant; Jill Marie (Chapel Hill, NC), Royalty; Susan M. (Davis, CA) |
| Assignee: | Aerie Pharmaceuticals, Inc. (Bedminster, NJ) |
| Application Number: | 16/138,837 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,532,993
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE | ⤷ Sign Up | ||||
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,532,993
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009273932 | ⤷ Sign Up | |||
| Canada | 2731869 | ⤷ Sign Up | |||
| European Patent Office | 2326623 | ⤷ Sign Up | |||
| Spain | 2474150 | ⤷ Sign Up | |||
| Japan | 2011529074 | ⤷ Sign Up | |||
| Japan | 2014208681 | ⤷ Sign Up | |||
| Japan | 5643758 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
